


CHEMICAL COMPOUNDS

The present invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

Thus the invention provides compounds of formula (I) which are agonists at the adenosine A1 receptor.



wherein R^2 represents C_{1-3} alkyl, halogen or hydrogen;

R^3 represents straight or branched alkyl group of 1-6 carbon atoms;

R^1 represents a group selected from

- (1) $-(alk)_n-$ (C_{3-7}) cycloalkyl, including bridged cycloalkyl, said cycloalkyl group being optionally substituted by one or more substituents selected from OH, halogen, $-(C_{1-3})$ alkoxy, wherein (alk) represents C_{1-3} alkylene and n represents 0 or 1.


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 19/00	A2	(11) International Publication Number: WO 99/24451 (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: PCT/EP98/07023 (22) International Filing Date: 6 November 1998 (06.11.98) (30) Priority Data: 9723590.7 8 November 1997 (08.11.97) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ELDRED, Colin, David [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). PENNELL, Andrew, Michael, Kenneth [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). (74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract

A compound of formula (I), wherein R^2 represents C_{1-3} alkyl, halogen or hydrogen; R^3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R^3 represents C_{1-3} alkyl, R^2 represents C_{1-3} alkyl, R^1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C_{1-3} alkyl, trifluoromethyl, nitro, cyano, $-CO_2R^e$, $-CONR^eR^d$, $-COR^e$, $-SOR^e$, $-SO_2R^e$, $-SO_3H$, $-SO_2NR^eR^d$, $-OR^e$, $-NHSO_2R^e$, $-NHCOR^e$ and $-NR^eR^d$; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- (2) an aliphatic heterocyclic group of 4 to 6 membered rings containing at least one heteroatom selected from O, N or S, optionally substituted by one or more substituents selected from the group consisting of $-(C_{1-3})$ alkyl, $-CO_2-(C_{1-4})$ alkyl, $-CO(C_{1-3})$ alkyl, $-S(=O)_n-(C_{1-3})$ alkyl, $CONR^aR^b$ (wherein R^a and R^b independently represent H or C_{1-3} alkyl) or $=O$, and where there is a sulfur atom in the heterocyclic ring, said sulfur is optionally substituted by $(=O)_n$ where n is 1 or 2.
- (3) Straight or branched C_{1-12} alkyl, optionally including one or more O, $S(=O)_n$, (where n is 0, 1 or 2) or N groups substituted within the alkyl chain, said alkyl optionally substituted by one or more of the following groups, phenyl, halogen, hydroxy or NR^aR^b wherein R^a and R^b both represent C_{1-3} alkyl or hydrogen.
- (4) a fused bicyclic aromatic ring



15

wherein B represents a 5 or 6 membered heterocyclic aromatic group containing 1 or more O, N or S atoms, wherein the bicyclic ring is attached to the nitrogen atom of formula (I) via a ring atom of ring A and ring B is optionally substituted by $-CO_2$ (C_{1-3} alkyl).

- (5) a phenyl group optionally substituted by one or more substituents selected from:
- halogen, $-SO_3H$, $-(alk)_nOH$, $-(alk)_n$ -cyano, $-(O)_n$ - C_{1-6} -alkyl (optionally substituted by one or more halogens), $-(alk)_n$ -nitro, $-(O)_m$ - $-(alk)_n$ - CO_2R^c , $-(alk)_n$ - $CONR^cR^d$, $-(alk)_n$ - COR^c , $-(alk)_n$ - SOR^e , $-(alk)_n$ - SO_2R^e , $-(alk)_n$ - $SO_2NR^cR^d$, $-(alk)_nOR^c$, $-(alk)_n$ $(CO)_m$ $NHSO_2R^e$, $-(alk)_n$ - $NHCOR^c$, $-(alk)_n$ - NR^cR^d wherein m and n are 0 or 1 and alk represents a C_{1-6} alkylene group or C_{2-6} alkenyl group.

25

- (6) A phenyl group substituted by a 5 or 6 membered heterocyclic aromatic group, said heterocyclic aromatic group optionally being substituted by C₁₋₃alkyl or NR^cR^d.

5 R^c and R^d may each independently represent hydrogen, or C₁₋₃ alkyl or when part of a group NR^cR^d, R^c and R^d together with the nitrogen atom may form a 5 or 6 membered heterocyclic ring optionally containing other heteroatoms which heterocyclic ring may optionally be substituted further by one or more C₁₋₃ alkyl groups.

R^e represents C₁₋₃alkyl;

10 With the proviso that, when R³ represents C₁₋₆ alkyl, R² represents C₁₋₃ alkyl, R¹ cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C₁₋₃alkyl, trifluoromethyl, nitro, cyano, -CO₂R^c, -CONR^cR^d, -COR^c, -SOR^e, -SO₂R^e, -SO₃H, -SO₂NR^cR^d, -OR^c, -NHSO₂R^e, -NHCOR^c and -NR^cR^d;

15 and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof.

20 Conveniently, the adenosine A1 agonists of general formula (I) above exhibit greater activity at the adenosine receptor than the other adenosine receptor subtypes, particularly A3. More preferably the compounds exhibit little or no activity at the adenosine A3 receptor.

25 It will be appreciated that wherein R¹ and/or R² in compounds of formula (I) contain one or more asymmetric carbon atoms the invention includes all diastereoisomers of compounds of formula (I) and mixtures thereof. Otherwise the stereochemical configuration of compounds of the invention is as depicted in formula (I) above.

30 As used herein, the term "alkyl" means a straight or branched chain alkyl group. Examples of suitable alkyl groups within R¹ and R² include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl and 2,2-dimethylpropyl.

As used herein, the term "C₂₋₆alkenyl" means a straight or branched chain alkenyl group containing 2 to 6 carbon atoms. Allyl represents an example of a suitable C₂₋₆alkenyl group.

5

As used herein the term "alkylene" means a straight or branched chain alkylene group containing 1 to 6 carbon atoms e.g. methylene.

The term "halogen" means fluorine, chlorine, bromine or iodine.

10

By aliphatic heterocyclic group is meant a cyclic group of 4-6 carbon atoms wherein one or more of the carbon atoms is/are replaced by heteroatoms independently selected from nitrogen, oxygen or sulfur. This group may optionally be substituted as defined hereinabove.

15

The term heterocyclic aromatic group refers to an aromatic mono or bicyclic ring system comprising from 5 to 10 carbon atoms wherein one or more of the carbon atoms is/are replaced by heteroatoms independently selected from nitrogen, oxygen and sulfur, which ring system may optionally be substituted as defined hereinabove.

20

Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from pharmaceutically acceptable inorganic and organic acids. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. A particularly suitable pharmaceutically acceptable salt of the compounds of formula (I) is the hydrochloride salt. Other acids such as oxalic, while not, in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. The solvates may be, for example, hydrates.

25

30

R^3 preferably represents a C_{1-3} alkyl group especially a methyl or ethyl group more preferably methyl.

R^2 preferably represents hydrogen, methyl or halogen, more preferably hydrogen or methyl.

- 5 Conveniently, R^1 may represent $(alk)_n$ - C_{5-7} cycloalkyl, including bridged cycloalkyl wherein n is 0 or 1 and the said cycloalkyl is either substituted by at least one substituent selected from halogen, particularly fluorine, $-(C_{1-3})$ alkoxy, particularly methoxy and OH or is unsubstituted. Preferably, when substituted the substituent is fluorine and, the cycloalkyl is mono-substituted. Preferably, n
10 represents zero.

- Alternatively R^1 may represent a substituted or unsubstituted aliphatic heterocyclic group, which when substituted, the substituent being selected from the group consisting of C_{1-3} alkyl, $-(CO_2)$ $-(C_{1-4})$ alkyl, $=O$, $-CO-(C_{1-3})$ alkyl, $-S(=O)_n-$ (C_{1-3}) alkyl (where n is 1 or 2), $CONR^aR^b$ wherein R^a and R^b are defined herein
15 above, and when there is a heteroatom S in the ring, this S is optionally substituted by $(=O)_n$ where n is 1 or 2. More preferably the substituents are $-CO_2C_{(1-4)}$ alkyl or methyl.

- Conveniently the aliphatic heterocyclic group is unsubstituted or when the substituent is $-CO_2(C_{1-4})$ alkyl the heteroatom is N and the substituent is directly
20 attached to said ring nitrogen atom.

Preferably the heterocyclic ring is 6 membered and more preferably contains only one N , O or S heteroatom.

- Alternatively, R^1 may represent a straight or branched alkyl of 1-6 carbon atoms optionally including at least one $S(=O)_2$, O or N substituted in the chain. The
25 alkyl group conveniently may be further substituted by at least one group selected from OH, phenyl and fluorine or is unsubstituted.

Alternatively R^1 may represent a phenyl group which is substituted by one or more substituents selected from OH, halogen, $(O)_m$ $(alk)_n$ CO_2R^c , and $-(alk)_nOH$. Preferably the phenyl is disubstituted in the 2,4 positions. Preferably both

substituents are halogen more particularly, fluorine and chlorine. For example, a particularly preferred combination is 2- fluoro and 4- chloro.

Alternatively R¹ represents a phenyl group substituted by a 5-tetrazolyl group, this group itself optionally substituted by C₁₋₃alkyl.

- 5 Alternatively R¹ represents a fused group.



wherein B represents a furan ring, said furan ring being optionally substituted by -CO₂(C₁₋₃)alkyl more preferably in the 2 position.

- 10 It is to be understood that the present invention covers all combinations of particular and preferred groups mentioned above.

Particular compounds according to the invention include:

- 5'-O-Methyl-N-(tetrahydro-furan-3R-yl)-adenosine
 N-(2R-Hydroxy-(R)-cyclopentyl)-5'-O-methyl-adenosine
 15 5'-O-Methyl-N-(tetrahydro-pyran-4-yl)-adenosine
 N-(2S-Methoxy-(S)-cyclopentyl)-5'-O-methyl-adenosine
 5'-O-Methyl-N-(2S-methyl-tetrahydro-furan-3R-yl)-adenosine
 N-(3-Chloro-4-hydroxy-phenyl)-5'-O-methyl-adenosine
 5'-O-Methyl-N-(1R-methyl-2-phenyl-ethyl)-adenosine
 20 N-tert-Butyl-5'-O-methyl-adenosine
 N-(2S-Fluoro-(S)-cyclopentyl)-5'-O-methyl-adenosine
 N-(2,3-Dihydroxy-propylamino)-5'-O-methyl-adenosine
 N-rel-[(1S,4R)-Bicyclo[2.2.1]hept-2R-yl]-5'-O-methyl-adenosine
 4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-piperidine-1-carboxylic acid ethyl ester
 25 5'-O-Methyl-N-[4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-adenosine
 3-[4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-phenyl]-(E)-acrylic acid

- N-(4-Hydroxymethyl-phenyl)-5'-O-methyl-adenosine
 {4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-
 ylamino]-phenoxy}-acetic acid
 5-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-
 5 ylamino]-benzofuran-2-carboxylic acid methyl ester
 5'-O-Methyl-N-(tetrahydro-thiopyran-4-yl)-adenosine
 N-rel-[(1R,5R)-Bicyclo[3.2.0]hept-6S-yl]-5'-O-methyl-adenosine
 4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-2-methyl-9H-
 purin-6-ylamino]-piperidin-2-one
 10 5'-O-Methyl-N-(1S-methoxymethyl-2-methyl-propyl)-adenosine
 N-(2-Hydroxy-1R-methyl-ethyl)-5'-O-methyl-adenosine
 N-(2-Fluoro-1R-methyl-ethyl)-5'-O-methyl-adenosine
 N-(1S-Fluoromethyl-2-methoxy-ethyl)-5'-O-methyl-adenosine
 N-(3-Amino-propyl)-5'-O-methyl-adenosine
 15 2-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-2-methyl-9H-
 purin-6-ylamino]-ethanesulfonic acid methylamide
 N-Cyclopentyl-2-methyl-5'-O-methyl-adenosine
 N-Cyclopropylmethyl-2-methyl-5'-O-methyl-adenosine
- 20 Compounds according to the invention have applicability as inhibitors of lipolysis
 i.e. they decrease plasma free fatty acid concentrations. The compounds may
 thus be used in the treatment of hyperlipidaemias. Furthermore, as a
 consequence of their anti-lipolytic activity, the compounds have the ability to
 lower elevated blood glucose, insulin and ketone body levels and therefore may
 25 be of value in the therapy of diabetes. Since anti-lipolytic agents have
 hypolipidaemic and hypofibrinogenaemic activity, the compounds may also
 show anti-atherosclerotic activity. The anti-lipolytic activity of compounds of the
 invention has been demonstrated by their ability to lower the concentration of
 non-esterified fatty acids (NEFA) in starved rats dosed orally according to the
 30 method described by P. Strong et al. in Clinical Science (1993), 84, 663-669.

In addition to their anti-lipolytic effect, the compounds of the invention may
 independently affect cardiac function by reducing heart rate and conduction.
 The compounds may thus be used in the therapy of a number of cardiovascular

disorders, for example cardiac arrhythmias, particularly following myocardial infarction, and angina.

5 Furthermore, the compounds of the invention are useful as cardioprotective agents, having applicability in the treatment of ischaemic heart disease. As used herein the term "ischaemic heart disease" includes damage associated with both myocardial ischaemia and reperfusion, for example, associated with coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), cardioplegia, acute myocardial infarction, thrombolysis, stable and
10 unstable angina and cardiac surgery including in particular cardiac transplantation. The compounds of the invention additionally are useful for treating ischaemic damage to other organs. The compounds of the invention may also be valuable in the treatment of other disorders arising as a result of widespread atheromatous disease, for example, peripheral vascular disease
15 (PVD) and stroke.

The compounds may also inhibit renin release and thus be of use in the therapy of hypertension and heart failure. The compounds may also be useful as CNS agents (e.g. as hypnotics, sedatives, analgesics and/or anti-convulsants
20 particularly finding use in the treatment of epilepsy).

In addition, the compounds of the invention may find use in the treatment of sleep apnoea.

25 The compound of formula (I) and pharmaceutically acceptable acid addition salts thereof are useful as analgesics. They are therefore useful in treating or preventing pain. They may be used to improve the condition of a host, typically of a human being, suffering from pain. They may be employed to alleviate pain in a host. Thus, the compound of formula (I) and its pharmaceutically
30 acceptable acid addition salts may be used as a preemptive analgesic to treat acute pain such as musculoskeletal pain, post operative pain and surgical pain, chronic pain such as chronic inflammatory pain (e.g. rheumatoid arthritis and osteoarthritis), neuropathic pain (e.g. post herpetic neuralgia, neuropathies associated with diabetes, trigeminal neuralgia and sympathetically maintained

5 pain) and pain associated with cancer and fibromyalgia. The compound of formula (I) may also be used in the treatment or prevention of pain associated with migraine, tension headache and cluster headaches, pain associated with functional bowel disorders (eg IBS), non cardiac chest pain and non ulcer dyspepsia.

10 Accordingly, the invention provides a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy, and in particular in the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or whereby the therapy involves the treatment of ischaemic heart disease, peripheral vascular disease or stroke or which subject is suffering from a CNS disorder, sleep apnoea or pain.

15 In a further aspect, the invention provides a method of treatment of a human or animal subject suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease or stroke, or which subject is suffering a CNS disorder or suffering from sleep apnoea or suffering pain, which method comprises administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

25 In respect of the above mentioned ischaemic treatment, it has been found that according to a particularly unexpected aspect of the present invention, not only does administration of a compound of formula (I) prior to ischaemia provide protection against myocardial infarction, but protection is also afforded if the compound of formula (I) is administered after the ischaemic event and before
30 reperfusion. This means that the methods of the present invention are applicable not only where ischaemia is planned or expected, for example in cardiac surgery, but also in cases of sudden or unexpected ischaemia, for example in heart attack and unstable angina.

It will be appreciated that reference to treatment includes acute treatment or prophylaxis as well as the alleviation of established symptoms.

5 In yet a further aspect, the invention provides a pharmaceutical composition comprising at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in association with a pharmaceutical carrier and/or excipient.

10 In another aspect, the invention provides a pharmaceutical composition comprising, as active ingredient, at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in association with a pharmaceutical carrier and/or excipient for use in therapy, and in particular in the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease or stroke, or which subject is suffering from a CNS disorder, sleep apnoea or pain.

20 There is further provided by the present invention a process of preparing a pharmaceutical composition, which process comprises mixing at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier and/or excipient.

25 Compositions according to the invention may be formulated for topical, oral, buccal, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred. The compositions may be adapted for sustained release.

30 For topical administration, the pharmaceutical composition may be conveniently given in the form of a transdermal patch.

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, microcrystalline cellulose or maize-starch;

lubricants, for example, magnesium stearate or stearic acid; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, or carboxymethyl cellulose; emulsifying agents, for example, sorbitan mono-oleate; non-aqueous vehicles (which may include edible oils), for example, propylene glycol or ethyl alcohol; and preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents (e.g. mannitol) as appropriate.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds of formula (I) may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The compounds of formula (I) may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.


A proposed dose of the compounds of the invention for administration to man (of approximately 70kg body weight) is 1mg to 2g, preferably 1mg to 100mg, of the active ingredient per unit dose which could be administered, for example, 1 to 4

times per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient. The dosage will also depend on the route of administration.

- 5 In a yet further aspect the invention also provides for the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which
10 subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease (PVD) or stroke, or which patient is suffering from a CNS disorder, sleep apnoea or pain.

- The compounds of formula (I) and physiologically acceptable salts or solvates thereof may be prepared by the processes described hereinafter, said
15 processes constituting a further aspect of the invention. In the following description, the groups R^1 , R^2 and R^3 are as defined for compounds of formula (I) unless otherwise stated.

- 20 According to a first general process (A), a compound of formula (I) may be prepared by reacting a compound of formula (II).




- 25 wherein, L represents a leaving group such as a halogen atom (e.g. a chlorine atom) and P^1 and P^2 represent hydrogen or a suitable protecting group (e.g. acetyl). with a compound of formula R^1NH_2 or a salt thereof, under basic conditions.


Compounds of formula (II) may be used to produce compounds of formula (I) directly by reaction with the group R^1NH_2 either in the absence or presence of a solvent such as an alcohol (e.g. a lower alkanol such as isopropanol, t-butanol or 3-pentanol), an ether (e.g. tetrahydrofuran or dioxan), a substituted amide (e.g. dimethylformamide), a halogenated hydrocarbon (e.g. chloroform) or acetonitrile, preferably at an elevated temperature (e.g. up to the reflux temperature of the solvent), in the presence of a suitable acid scavenger, for example, inorganic bases such as sodium or potassium carbonate, or organic bases such as triethylamine, diisopropylethylamine or pyridine.

This reaction may be preceded or followed where appropriate by in situ removal of the P^1 and P^2 protecting groups. For example when P^1 and P^2 represent acetyl, this may be effected with an amine such as ammonia or tert-butylamine in a solvent such as methanol.

Compounds of formula (II) may be prepared by the reaction of a compound of formula (III).



wherein P^3 represents a suitable protecting group for example C_{1-3} alkyl or acetyl, and P^1 , P^2 and R^3 are as defined above, with a compound of formula (IV)




wherein L and R^2 are as defined above.

The reaction is conveniently carried out in a suitable solvent, such as acetonitrile in the presence of a silylating agent such as trimethylsilyl trifluoromethane

sulfonate and a base such as diazabicyclo [5.4.0]undec-7-ene (DBU). Alternatively the compound of formula (IV) may first be silylated with a suitable silylating agent e.g. hexamethyldisilazane followed by reaction of the silylated intermediate with a compound of formula (III) and a suitable Lewis acid, e.g. trimethylsilyl trifluoromethane sulfonate in a suitable solvent such as acetonitrile.

Compounds of formula (IV) are either known in the art or may be prepared from known compounds using methods analogous to those used to prepare the known compounds of formula (IV).

Compounds of formula (III) may be prepared from alternative protected compounds by replacement of the alternate protecting groups with P^1 and P^2 , for example when P^1 and P^2 represent acetyl, compounds of formula (III) may be prepared from compounds of formula (V), wherein P^4 and P^5 represent C_{1-3} alkyl and P^3 is as defined above, by acid catalysed removal of the alkylidene protecting group, e.g. with hydrogen chloride in methanol, followed by in situ acylation for example with acetic anhydride in the presence of a base such as pyridine, in a solvent such as dichloromethane.



Compounds of formula (V) are known compounds or prepared by methods analogous to those used in the art to prepare the known compounds of formula V. It will be appreciated by a skilled person that the acetyl group in any of the compounds above could be replaced with any suitable protecting group, for example, other esters.

By analogous methods, compounds of formula (I) or (II) may also be prepared from compounds wherein alkylidene groups defined by P^4 and P^5 replace P^1 and

P². This reaction represents an exchange of one protecting group for another and such reactions will be apparent to a person skilled in the art.

5 A further process (B) comprises converting a compound of formula (I) into a different compound of formula (I) by modifying the R¹, R² or R³ group therein.

Certain compounds of formulae (II), (III), (IV), and (V) are novel intermediates and form a further aspect of the present invention.

10 Compounds of the formula R¹NH₂ are either known compounds or may be prepared from known compounds using conventional procedures.

15 Specific optical isomers of a compound of formula (I) may be obtained by conventional methods for example, by synthesis from an appropriate asymmetric starting material using any of the processes described herein, or where appropriate by separation of a mixture of isomers of a compound of formula (I) by conventional means e.g. by fractional crystallisation or chromatography.

20 In the general processes described above, the compound of formula (I) obtained may be in the form of a salt, conveniently into the form of a pharmaceutically acceptable salt. Where desired, such salts may be converted into the corresponding free bases using conventional methods.

25 Pharmaceutically acceptable acid addition salts of the compounds of formula (I) may be prepared by reacting a compound of formula (I) with an appropriate acid in the presence of a suitable solvent such as acetonitrile, acetone, chloroform, ethyl acetate or an alcohol (e.g. methanol, ethanol or isopropanol). Pharmaceutically acceptable base addition salts may be obtained in an
30 analogous manner by treating a solution of a compound of formula (I) with a suitable base. Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts of the compounds of formula (I), using conventional methods.

The invention is further illustrated by the following non-limiting Intermediates and Examples. Temperatures are in °C.

Standard HPLC conditions are as follows:

5

Standard Automated Preparative HPLC column, conditions & eluent

Automated preparative high performance liquid chromatography (autoprep. HPLC) was carried out using a Supelco ABZ+ 5 μ m 100mmx22mm i.d. column
10 eluted with a mixture of solvents consisting of i) 0.1% formic acid in water and ii) 0.05% formic acid in acetonitrile, the eluant being expressed as the percentage of ii) in the solvent mixture, at a flow rate of 4ml per minute. Unless otherwise stated the eluent was used as a gradient of 0-95 % (ii) over 20 minutes.

15 **LC/MS System (5.5min run time)**

This system used an ABZ+PLUS, 3.3cm x 4.6mm i.d. column, eluting with solvents: A - 0.1%v/v formic acid; and B - 95:5 acetonitrile:water + 0.07%v/v formic acid, at a flow rate of 1.5ml per minute. The following gradient protocol
20 was used: 100% A for 0.2 mins; A+B mixtures, gradient profile 0 - 100% B over 3.5mins; hold at 100% B for 1 min; return to 100% A over 0.2 mins. The system used a micromass 'platform' spectrometer, with electrospray ionisation mode, positive and negative ion switching, mass range 80-1000 a.m.u.

25 **HPLC System**

The analytical HPLC system used a BDS-C18 5 μ 5591 column, eluting with acetonitrile / water starting at 30% acetonitrile / water increasing to 60% acetonitrile over 10 mins with a flow rate of 1.0 mL/min. This system used a
30 diode array detector monitoring at a wavelength of 226 nm UV.

Flash chromatography was carried out over Merck silica gel (Merck 9385) , or Merck alumina (Merck 1077).

Intermediate 1Acetic acid 4R-acetoxy-5-methoxy-2R-methoxymethyl-tetrahydro-furan-3R-yl ester

- 5 Acetyl chloride (29.4ml) was added to methanol (1806ml), (3aR,4R,6R,6aR)-4-methoxy-6-methoxymethyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole [Gudmundsson et al; J Med. Chem. (1997) 40(S), 785-793] (90.3g) was added, and the mixture was heated under reflux for 5 days, during which time methanol was continuously distilled off and replaced with fresh methanol in order to drive
- 10 the reaction near to completion. Pyridine (117ml) was added, and the methanol was replaced by ethyl acetate by distilling off the solvent and replacing with ethyl acetate until the solvent was distilling at 76°. The volume was reduced to 400 ml, the mixture cooled to 22°, acetic anhydride (136ml) added, and the mixture was stirred at 22° for 16h. The mixture was poured into saturated aqueous
- 15 sodium bicarbonate (500ml), and solid sodium bicarbonate was added until pH>7 was obtained. After stirring for 30 min, the aqueous layer was separated and further extracted with ethyl acetate. The combined organic layers were dried (MgSO₄), evaporated *in vacuo*, and azeotroped with toluene. Distillation at 0.042mbar gave the title compound as a colourless oil (43.6g).
- 20 TLC SiO₂ [isohexane:ethyl acetate 1:1] 2 spots (α and β anomers), R_f = 0.6, 0.7.

Intermediate 2Acetic acid 4R-acetoxy-2R-(6-chloro-purin-9-yl)-5R-methoxymethyl-tetrahydro-furan-3R-yl ester

- 25 6-Chloropurine (3.53g), 1,1,1,3,3,3-hexamethyldisilazane (12ml) and toluene (40ml) were heated under reflux under nitrogen for 105 min. The solvent was removed *in vacuo*. The residue was taken into dry acetonitrile (50ml) and treated with acetic acid 4R-acetoxy-5-methoxy-2R-methoxymethyl-tetrahydro-furan-3R-yl ester (2.00g) and trimethylsilyl trifluoromethanesulfonate (1.9ml)
- 30 then heated under reflux for 4.5h. The resulting solution was cooled to 20°, poured into 8% sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were dried (MgSO₄) and evaporated *in vacuo* and the residue purified by flash chromatography on silica gel, eluting with cyclohexane-ethyl acetate (5:1-3:1 gradient) to afford the title compound (2.3g).

Mass spectrum m/z 385 (MH^+).

Intermediate 3

6-Chloro-9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purine

- 5 6-Chloro-9-[2,3-O-(1-methylethylidene)- β -D-ribofuranosyl]-9H-purine [H Guilford, PO Larsson, K Mosbach, *Chem. Scr.*, 1972, 2(4), 165-170] (6.0g) was dissolved in dry dioxan (150 mL) and sodium hydride (60% oil dispersion, 0.75g) added in portions over 10 mins at room temperature. The mixture was stirred
10 for 0.5h and dry benzyltriethylammonium chloride (1.5g) added. After a further 0.25h, dimethylsulphate (3mL; 4.0g; 31.6mmol) was added and stirring continued overnight to give a slightly cloudy solution. After a total of 24h, acetic acid (1.5mL) was added and the solution evaporated to dryness and the residual oil partitioned between water and ethyl acetate. The combined organic phases
15 were dried and concentrated *in-vacuo*. The residue purified by flash chromatography on silica gel, eluting with cyclohexane-ethyl acetate (1:1) to afford the title compound as a colourless oil, (2.5g)
TLC SiO_2 [EtOAc: cyclohexane: 2:1] R_f = 0.50.

20 Intermediate 3 (alternative method)

6-Chloro-9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purine

- A mixture of 6-chloro-9-[2,3-O-(1-methylethylidene)- β -D-ribofuranosyl]-9H-purine (0.50g), silver (I) oxide (0.40g) and methyl iodide (10 mL) in acetone (10mL)
25 were stirred at reflux for 4h then left at room temperature for 40h. The mixture was returned to reflux for 6h and then left to cool to room temp for 16h. The precipitate was filtered through hyflo and the filtrate concentrated *in-vacuo* then purified by flash chromatography on silica gel, eluting with cyclohexane-ethyl acetate (2:1 to 1:1) to afford the title compound as a colourless oil (151mg)
30 TLC SiO_2 [EtOAc: cyclohexane: 1:1] R_f = 0.2.

Intermediate 4

(2R,3R,4S,5R)-2-(6-Chloro-purin-9-yl)-5-methoxymethyl-tetrahydro-furan-3,4-diol

Cold trifluoroacetic acid (6 ml) was added to the 6-chloro-9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purine, (1.5g) cooled in ice. Water (0.6ml) was added and the mixture stirred at 4° for 3h. The cold solution was added in portions to cold 8% sodium bicarbonate (40 ml) and the mixture basified by adding solid sodium bicarbonate. The mixture was extracted with ethyl acetate and the extracts dried and concentrated *in-vacuo* to give the title compound as a white foam (1.3g; 98%).

Tlc SiO₂ [EtOAc: cyclohexane 1:2] R_f = 0.20.

10 Intermediate 5

(1R,2R)-2-[9-(6R-Methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purin-6-ylamino]-cyclopentanol

A solution of 6-chloro-9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purine (350mg), (1R,trans)-2-hydroxy-cyclopentylamine hydrochloride (155mg) and N,N-diisopropylethylamine (0.61ml) in isopropanol (5ml) was stirred at reflux under nitrogen for 18h. The reaction mixture was concentrated *in-vacuo* and the residue was purified by flash chromatography on silica gel, eluting with toluene:ethanol: triethylamine (90:10:1) to give a white foam (395mg).

TLC SiO₂ [toluene:ethanol:triethylamine 90:10:1] R_f = 0.41.

Intermediate 6

25 4-[9-(6R-Methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purin-6-ylamino]-benzoic acid methyl ester

A solution of 6-chloro-9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purine (1.0g), methyl 4-aminobenzoate (1.11g) and N,N-diisopropylethylamine (1.54mL) in isopropanol (25mL) was stirred at reflux under nitrogen. Two further portions of diisopropylethylamine (1.03mL) were added after 6 days and 13 days. After a total of 17 days the solution was concentrated and purified by flash chromatography on silica gel, eluting with ethyl acetate:cyclohexane (1:2). This gave the title compound as a white foam (668mg).

TLC SiO₂ [EtOAc:cyclohexane 1:2] R_f = 0.11.

Intermediate 7

5 4-[9-(6R-Methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purin-6-ylamino]-phenyl)-methanol

A solution of 4-[9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purin-6-ylamino]-benzoic acid methyl ester (100mg) in THF (5ml) was added to a suspension of lithium aluminium hydride (10mg) in THF (4ml) under nitrogen. The resulting mixture was stirred at room temperature for 3h. More lithium aluminium hydride (0.705mmol) was added in 2 portions over 6h. After a total of 21h, the reaction mixture was quenched with water (0.05ml), followed by sodium hydroxide solution (3N, 0.05ml), then further addition of water (0.15ml). The mixture was stirred for 1h and the solid removed by filtration (hyflo) and washed with methanol. The filtrate and washings were concentrated *in-vacuo* to give a yellow solid. This was purified by flash chromatography on silica gel, eluting with cyclohexane:ethyl acetate (1:9) to give the title compound as a yellow oil (33mg).

TLC silica [EtOAc] R_f = 0.30

20

Intermediate 8

Acetic acid 4R-acetoxy-2R-(6-chloro-2-methyl-purin-9-yl)-5R-methoxymethyl-tetrahydro-furan-3R-yl ester.

6-Chloro-2-methyl-9H-purine hydrochloride [Robins et al; J. Org. Chem, 1956, 21, 695-696] (18.4g) was added at 20° to a stirred solution of acetic acid 4R-acetoxy-5-methoxy-2R-methoxymethyl-tetrahydro-furan-3R-yl ester (intermediate 1) (20.0g) in acetonitrile (200ml). 1,8-Diazabicyclo [5.4.0] undec-7-ene (DBU) (34.2ml) was added in 2 portions, maintaining the temperature at 15±5°. After stirring for 5 min at 20°, trimethylsilyl trifluoromethanesulphonate (73.7ml) was added dropwise over 3 min, maintaining the temperature at 20°. The mixture was warmed to 60° for 2h, and transferred via cannula into water (400ml) containing potassium carbonate (84g). The mixture was extracted with ethyl acetate (4 x 100ml), and the organic layers were washed with 0.5M hydrochloric acid (200ml) and aqueous potassium carbonate, dried (MgSO₄),

and evaporated in vacuo. The oily residue was purified by chromatography on silica gel, eluting with ethyl acetate, and by recrystallation from ethyl acetate to give the title compound (16.5g).

TLC SiO₂ [Ethyl acetate: cyclohexane 1:1] R_f = 0.2

5 Mass Spectrum m/z 399 [MH⁺]

Intermediate 9

2,5'-O-Dimethyl-2',3'-O-(1-methylethylidene)inosine

10 A solution of 2-methyl-2',3'-(1-methylethylidene)inosine [A Yamazaki et al., J. Org.Chem. 1967, 32, 3258] (4.0g) in dry dimethylformamide (31ml) was added dropwise to an ice-cooled suspension of sodium hydride (60% dispersion in oil, 1.09g) in dry dimethylformamide (8ml). The resulting suspension was stirred at room temperature for 2 hours, recooled to 0° and treated with iodomethane (0.82ml). The reaction mixture was stirred at room temperature for 20 hours,
15 acetic acid (1.54ml) was added and stirring was continued for a further 24 hours. The solvent was removed under vacuum and the residue was purified by flash chromatography on a silica column eluting with dichloromethane/methanol/ammonia (97:3:0.5 changing to 95:5:0.5) to give the title compound (1.16g) as a light brown foam.

20 T.l.c. SiO₂ [dichloromethane/methanol/ammonia 90:10:1] R_f = 0.38.

Intermediate 10

1-(6-Chloro-2-methyl-9H-purin-9-yl)-1-deoxy-5-O-methyl-2,3-O-(1-methylethylidene)-β-D-ribofuranose

25 Phosphorus oxychloride (0.8ml) was added to a mixture of Intermediate 9 (1.16g) and 4-dimethylaminopyridine (462mg) in dry acetonitrile (15ml) which was then stirred at reflux for 2.75 hours. The cooled solution was concentrated under vacuum and the residue was basified using 2N sodium carbonate (75ml). The aqueous mixture was extracted with ethyl acetate (x2) and the combined
30 organic extracts were dried (Na₂SO₄) and concentrated to a brown oil which was purified by flash chromatography on a silica column eluting with cyclohexane/ethyl acetate (1:1) to give the title compound (436mg) as a colourless oil.

T.l.c. SiO₂ (cyclohexane/ethyl acetate 1:1) R_f = 0.29.

Intermediate 111-(6-Chloro-2-methyl-9H-purin-9-yl)-1-deoxy-5-O-methyl-b-D-ribofuranose

Ice-cold Intermediate 2 (415mg) was treated with an ice-cold mixture of trifluoroacetic acid (4.2ml) and water (0.42ml) and the reaction mixture was stirred at 0° for 1.5 hours. Excess trifluoroacetic acid was removed under vacuum and the residue was purified by flash chromatography on a silica column (Merck 9385, dichloromethane/methanol/ammonia 130:10:1) to give the title compound (276mg) as a white solid.

T.l.c. silica (dichloromethane/methanol/ammonia 90:10:1) Rf 0.48.

In an alternative method intermediate 11 was synthesised by the following procedure.

tert-Butylamine (3.5ml) was added to a cooled suspension of acetic acid 4R-acetoxy-2R-(6-chloro-2-methyl-purin-9-yl)-5R-methoxymethyl-tetrahydro-furan-3R-yl ester ('intermediate 8') (4.75g) in methanol (53ml), and the mixture was stirred at 0° for 1.5h. The mixture was filtered, and the residue washed with methanol and dried in vacuo at 50° to give the title compound as a white powder (0.9g). Concentration of the mother liquors in vacuo and trituration of the residue with diisopropyl ether (25ml) gave further title compound (2.6g) as a white powder.

Example 15'-O-Methyl-N-(tetrahydro-furan-3R-yl)-adenosine

A mixture of (2R,3R,4S,5R)-2-(6-chloro-purin-9-yl)-5-methoxymethyl-tetrahydro-furan-3,4-diol (125mg), (3R)-3-aminotetrahydrofuran hydrochloride (62mg), N,N-diisopropylethylamine (0.27ml) and isopropanol (5ml) was heated at reflux for 24h and then cooled to room temperature. Silica (Merck 7734) was added and the mixture concentrated *in vacuo*. The solid residue was purified by flash chromatography on silica gel, eluting with ethyl acetate:methanol (19:1). The resulting white solid was recrystallised from ethyl acetate to provide the title compound as a white powder (90mg)

Analysis Found: C, 50.3; H, 5.9; N, 19.5. $C_{15}H_{21}N_5O_5 \cdot 0.3 H_2O$ requires: C, 50.5; H, 6.1; N, 19.6%.

mp = 179-180 °C

- 5 The following examples were all prepared from Intermediate 4 by analogous methods to Example 1, using reaction times and stoichiometry depending on the reactivity of the amine.

Example 2 5'-O-Methyl-N-(tetrahydro-pyran-4-yl)-adenosine

10 Analysis Found: C, 52.7; H, 6.5; N, 18.9. $C_{16}H_{23}N_5O_5$ requires: C, 52.6; H, 6.3; N, 19.2%.

mp = 133-134 °C

Example 3 N-(2S-Methoxy-(S)-cyclopentyl)-5'-O-methyl-adenosine

15 Analysis Found: C, 53.1; H, 6.7; N, 18.3. $C_{17}H_{25}N_5O_5 \cdot 0.25 H_2O$ requires: C, 53.2; H, 6.7; N, 18.2%.

Nmr in d_6 -DMSO 8.36 δ (1H, s, CH), 8.26 δ (1H, brs, CH), 7.81 δ (1H, brd, NH), 5.96 δ (1H, d, CH), 5.6 δ (1H, brd, OH), 5.37 δ (1H, brd, OH), 4.7-4.55 δ (2H, brm, 2xCH), 4.18 δ (1H, brm, CH), 4.05 δ (1H, m, CH), 3.85 δ (1H, m, CH), 3.6 δ (2H, m, 20 CH₂), 3.33 δ (3H, s, OMe), 3.28 δ (3H, s, OMe), 2.1-1.5 δ (6H, 2xm, 3xCH₂).

Example 4 5'-O-Methyl-N-(2S-methyl-tetrahydro-furan-3R-yl)-adenosine

TLC SiO₂ [EtOAc: MeOH 9:1] R_f = 0.30

mp = 156-159 °C

25

Example 5 N-(3-Chloro-4-hydroxy-phenyl)-5'-O-methyl-adenosine

mp = 225-230 °C

LC/MS: R_t = 2.45min; Mass spectrum m/z 408 (MH⁺)

30 **Example 6** 5'-O-Methyl-N-(1R-methyl-2-phenyl-ethyl)-adenosine

Analysis Found: C, 58.5; H, 6.3; N, 17.0. $C_{20}H_{25}N_5O_4 \cdot 0.6 H_2O$ requires: C, 58.6; H, 6.4; N, 17.1%.

LC/MS: R_t = 2.63min; Mass spectrum m/z 400 (MH⁺)

- Example 7** 5'-O-Methyl-N-[4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-adenosine
 LC/MS : R_t = 2.57min; Mass spectrum m/z 440 (MH^+)
- 5 **Example 8** 3-{4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-phenyl}-(E)-acrylic acid
 TLC SiO_2 [CH_2Cl_2 : EtOH: 880NH₃ 5:8:1] R_f = 0.15
 mp = 257-263 °C
- 10 **Example 9** {4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-phenoxy}-acetic acid
 Analysis Found: C, 48.9; H, 4.6; N, 14.9. $C_{19}H_{21}N_5O_7$. requires: C, 48.8; H, 5.4; N, 15.0%.
 mp = 210-215 °C
- 15 **Example 10** 5-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-benzofuran-2-carboxylic acid methyl ester
 LC/MS : R_t = 2.67min; Mass spectrum m/z 456 (MH^+)
- 20 **Example 11** 5'-O-Methyl-N-(tetrahydro-thiopyran-4-yl)-adenosine
 Analysis Found: C, 49.8; H, 6.2; N, 18.0; S, 8.4. $C_{16}H_{23}N_5O_4$ S. 0.25 H₂O requires: C, 49.8; H, 6.1; N, 18.1; S 8.3%.
 TLC SiO_2 [EtOAc: MeOH:19:1] R_f = 0.46
- 25 **Example 12** N-rel-[(1R,5R)-Bicyclo[3.2.0]hept-6S-yl]-5'-O-methyl-adenosine
 TLC SiO_2 [EtOAc: MeOH: 30:1] R_f = 0.21
 Analysis Found: C, 56.4; H, 6.9; N, 17.5. $C_{18}H_{25}N_5O_4$. 0.05 H₂O . 0.2 ¹PrOH requires: C, 56.4; H, 7.0; N, 17.7%.
- 30 **Example 13** 5'-O-Methyl-N-(1S-methoxymethyl-2-methyl-propyl)-adenosine
 TLC SiO_2 [CH_2Cl_2 : MeOH: 880NH₃ 120:8:1] R_f = 0.30
 Nmr d_6 -DMSO 8.33δ (1H, brs, CH) 8.25-8.10δ (1H, 2 x brs, CH) 7.45δ (1H, brd, NH), 5.92δ (1H, d, CH) 5.55δ (1H, brd, OH) 5.3δ (1H, brd, OH) 5.1,4.4δ (1H, 2 x

brs, CH) 4.62δ (1H, brs, CH) 4.18δ (1H, m, CH) 4.02δ (1H, m, CH) 3.5-3.2δ (11H, m + 3 x s, CH + 2 x CH₂ + 2 x OCH₃) 1.95δ (1H, m, CH) 0.92δ (6H, 2 x d, 2 x CH₃).

5 **Example 14** N-(2-Hydroxy-1R-methyl-ethyl)-5'-O-methyl-adenosine
Analysis Found: C, 49.2; H, 6.2; N, 20.4. C₁₄H₂₁N₅O₅. requires: C, 49.6; H, 6.2; N, 20.6%.
mp = 232-233 °C

10 **Example 15** N-(2-Fluoro-1R-methyl-ethyl)-5'-O-methyl-adenosine
TLC SiO₂ [EtOAc: MeOH 30:1] R_f = 0.21
HPLC R_t=9.4 min

15 **Example 16** N-(1S-Fluoromethyl-2-methoxy-ethyl)-5'-O-methyl-adenosine
TLC SiO₂ [EtOAc: MeOH 30:1] R_f = 0.16
HPLC R_t=10.0 min

20 **Example 17** N-(2R-Hydroxy-(R)-cyclopentyl)-5'-O-methyl-adenosine
(1R,2R)-2-[9-(6R-Methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purin-6-ylamino]-cyclopentanol (235mg) was cooled in an ice-bath, then treated with ice-cold trifluoroacetic acid:water (10:1, 2.75ml). After 1h the solution was concentrated *in-vacuo* and the residue was purified by flash chromatography on silica gel, eluting with dichloromethane:methanol:ammonia 94:6:1, then 90:10:1. The crude product
25 was triturated with warm ethyl acetate, then cold ether to give the title compound as a white solid (130mg).
Analysis Found: C, 52.8; H, 6.6; N, 19.2. C₁₆H₂₃N₅O₅ requires: C, 52.6; H, 6.3; N, 19.2%.
mp = 202-204 °C

30 **Example 18** N-(3-Amino-propyl)-5'-O-methyl-adenosine
This compound was prepared by analogous means to Example 17.
Analysis Found: C, 45.6; H, 6.2; N, 21.6. C₂₀H₂₅N₅O₄. 1.7 H₂O requires: C, 45.6; H, 6.9; N, 22.7%.

LC/MS : R_t = 1.69min; Mass spectrum m/z 339 (MH^+)

Example 19 N-tert-Butyl-5'-O-methyl-adenosine

Acetic acid 4R-acetoxy-2R-(6-chloro-purin-9-yl)-5R-methoxymethyl-tetrahydrofuran-3R-yl ester (1.15g) was dissolved in methanol (15ml), cooled to 0-5°, and tert-butylamine (10ml) added. The solution was allowed to stand at 0-5° for 1h, then evaporated to dryness *in vacuo*, to afford a white solid (0.99g) which was purified by flash chromatography on silica gel, eluting with dichloromethane methanol (99:1-4:1) to afford intermediate 2 as a white solid and also the title compound as a white solid (44mg).

Mass spectrum m/z 338 (MH^+)

Nmr $CDCl_3$ 8.28δ (1H, s, CH), 8.04δ (1H, s, CH), 6.5δ (1H, vbrs, OH), 6.0δ (1H, d, CH), 5.82δ (1H, brs, OH), 4.5-4.35δ (3H, m, 3xCH), 3.8-3.55δ (3H, brs+m, NH+CH₂), 3.385 (3H, s, OMe), 1.57δ (9H, s, t-But).

Example 20 N-(2S-Fluoro-(S)-cyclopentyl)-5'-O-methyl-adenosine

Acetic acid 4R-acetoxy-2R-(6-chloro-purin-9-yl)-5R-methoxymethyl-tetrahydrofuran-3R-yl ester (50mg), (1S,2S)-2-fluorocyclopentylamine hydrochloride (71mg) and diisopropylethylamine (0.14ml) were heated at 80° in isopropanol (5ml) in a reactivial for 17h. The solution was evaporated under a stream of nitrogen and purified by autoprep HPLC to afford the title compound as a colourless solid (33mg).

Mass spectrum m/z 368 (MH^+)

Nmr d_4 -MeOD 8.4δ (1H, s, CH), 8.3δ (1H, s, CH), 6.08δ (1H, d, CH), 5.05δ (1H, dm, CH, JF-CH 50Hz), 4.70δ (1H, br, CH), 4.56δ (1H, t, CH), 4.32δ (1H, t, CH), 4.2δ (1H, m, CH), 3.69δ (2H, m, CH₂), 3.45 (3H, s, -OMe), 2.4-1.65 (6H, m, 3xCH₂).

The following were prepared from Intermediate 20 by analogous methods to Example 20.

Example 21 N-(2,3-Dihydroxy-propylamino)-5'-O-methyl-adenosine

Mass spectrum m/z 356 (MH^+)

Nmr d_4 -MeOD 8.33 δ (1H, s, CH), 8.26 δ (1H, s, CH), 6.04 δ (1H, d, CH), 4.65 δ (1H, t, CH₂), 4.34 δ (1H, t, CH), 4.24 δ (1H, q, CH), 3.94 δ (1H, m, CH), 3.58-3.68 δ (6H, m, 3xCH), 3.40 δ (3H, s, -OMe).

5 **Example 22** N-rel-[(1S,4R)-Bicyclo[2.2.1]hept-2R-yl]-5'-O-methyl-adenosine

Mass spectrum m/z 376 (MH⁺)

Nmr d_4 -MeOD 8.36 δ (1H, brs, CH), 8.24 δ (1H, s, CH), 6.04 δ (1H, d, CH), 4.54 δ (1H, t, CH), 4.42-4.20 δ (2H, brs+t, 2xCH), 4.15 δ (1H, m, CH), 3.64 δ (2H, ddd, CH₂), 3.40 δ (3H, s, -OMe), 2.60 δ (1H, t, CH), 2.36-2.10 δ (2H, m+t, 2xCH), 1.76-1.36 (6H, m, CH₂), 1.1 δ (1H, ddd, CH).

15 **Example 23** 4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-piperidine-1-carboxylic acid ethyl ester

Mass spectrum m/z 437 (MH⁺)

Nmr d_4 -MeOD 8.33 δ (1H, s, CH), 8.25 δ (1H, s, CH), 6.05 δ (1H, d, CH), 4.58 δ (1H, t, CH), 4.33 δ (2H, t+brs, 2xCH), 4.15 δ (3H, q+m, CH₂+CH), 3.7 δ (2H, m, CH₂), 3.45 δ (3H, s, -OMe), 3.1 δ (2H, brt, CH₂), 1.6 δ (4H, m, CH₂), 1.28 δ (3H, t, CH₃).

20 **Example 24** N-(4-Hydroxymethyl-phenyl)-5'-O-methyl-adenosine

Cooled trifluoroacetic acid (4.0ml) and water (0.4ml) were added to ice-cold {4-[9-(6R-methoxymethyl-2,2-dimethyl-tetrahydro-(3aR,6aR)-furo[3,4-d][1,3]dioxol-4R-yl)-9H-purin-6-ylamino]-phenyl}-methanol (370mg) and stirred for 1.5h. This was then added dropwise to an ice-cold solution of sodium bicarbonate (8%, 40ml) and further sodium bicarbonate was added until the pH remained at pH8 to 9. This was extracted with ethyl acetate, the organic layers combined, dried (Na₂SO₄) and concentrated to give a white solid (~300mg). This was purified by flash chromatography on silica gel, eluting with dichloromethane, methanol, 0.88 ammonia (923:70:7) to give the title compound as a white solid. TLC SiO₂ [Dichloromethane, methanol, 0.88 ammonia (923:70:7)] R_f = 0.14 LC/MS : R_t = 2.23min; Mass spectrum m/z 338 (MH⁺).

Example 25 2-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-2-methyl-9H-purin-6-ylamino]-ethanesulfonic acid methylamide

A mixture of 1-(6-chloro-2-methyl-9H-purin-9-yl)-1-deoxy-5-O-methyl-β-D-ribofuranose, (0.15g) and 2-aminoethanesulfonic acid methylamide hydrochloride (0.13g) in isopropanol (12ml) containing diisopropylethylamine (0.3ml) was stirred at 95° for 42h under nitrogen. The solution was then cooled to room temperature and concentrated *in vacuo* to give a yellow gum (0.47g) which was purified twice by flash chromatography on silica gel, eluting with dichloromethane : ethanol: ammonia (100:8:1 - 75:8:1) and dichloromethane: ethanol: ammonia (100:8:1) to give the title compound (52mg) as a pale yellow solid.

Mass spectrum *m/z* 417 (MH⁺)

Analysis Found: C, 42.6; H, 5.6; N, 19.6. C₁₅H₂₄N₆O₆S. requires: C, 43.3; H, 5.8; N, 20.2%.

The following compounds were prepared from 1-(6-chloro-2-methyl-9H-purin-9-yl)-1-deoxy-5-O-methyl-β-D-ribofuranose by analogous methods to Example 26.

Example 26 4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-2-methyl-9H-purin-6-ylamino]-piperidin-2-one

TLC SiO₂ [CH₂Cl₂: MeOH: 880NH₃ 94:6:1] R_f = 0.05

LC/MS : R_t = 1.95min; Mass spectrum *m/z* 393 (MH⁺)

Example 27 N-Cyclopentyl-2-methyl-5'-O-methyl-adenosine

TLC SiO₂ [CH₂Cl₂: MeOH: 880NH₃ 94:6:1] R_f = 0.21

LC/MS : R_t = 2.28min; Mass spectrum *m/z* 364 (MH⁺)

Example 28 N-Cyclopropylmethyl-2-methyl-5'-O-methyl-adenosine

Acetic acid 4R-acetoxy-2R-(6-chloro-2-methyl-purin-9-yl)-5R-methoxymethyl-tetrahydro-furan-3R-yl ester (50mg), cyclopropylmethylamine (0.043ml) and diisopropylethylamine (0.13ml) were heated to reflux in isopropanol (5ml) for 120h. On cooling to room temperature, methanolic ammonia (4ml) was added to the reaction mixture, shaken and left to stand for 1 day. The solvent was

evaporated under a stream of nitrogen, and the residue purified by solid phase extraction (5g Varian Bondelut cartridge, aminopropyl bonded phase) to give the title compound (32mg) as a white solid.

Mass spectrum m/z 350 (MH^+)

5 Nmr d_4 -MeOD 8.25 δ (1H, s, CH), 6.08 δ (1H, d, CH), 4.57 δ (1H, t, CH), 4.34 δ (1H, t, CH), 4.2 δ (1H, m, CH), 3.7 δ (2H, m, CH₂), 3.48 δ (5H, m+s, CH₂+OMe), 2.5 δ (3H, s, -CH₃), 1.2 δ (1H, m, CH), 0.65-0.28 δ (4H, 2xm, 2xCH₂).

Reporter Gene Experiments

10

Agonist activity was measured in Chinese hamster ovary (CHO) cells containing the CRE/SPAP/HYG (CRE = cyclic AMP response element; HYG = hygromycin; SPAP = secreted placental alkaline phosphatase) reporter gene, which upon stimulation of cAMP levels produced SPAP. A cell line was used, which stably co-expresses the human adenosine A1 receptor. Cells were plated out in 96-well plates in culture medium and incubated at 37°C for 1 hour. For measurement of potency, agonists were added to the appropriate wells at a concentration range of approximately 10^{-10} - 10^{-5} M. 15Min later, cAMP levels were stimulated by addition of a maximal concentration of forskolin. All cells were then incubated for a further 5 hours at 37°C, and cooled to room temperature, after which a substrate for the phosphatase (para-nitrophenol phosphate, pNPP), which is broken down to a coloured reagent) was then added and the 96-well plates are read in a plate reader. From these readings, the concentration-dependence of the inhibition by the agonist of forskolin-stimulated SPAP production, can be calculated. One of the agonists tested on each 96-well plate was the standard non-selective agonist, N-ethylcarboxamidoadenosine (NECA), and the potency of all test agonists is expressed relative to that of the NECA standard.

15

20

25

(ECR = equipotent concentration ratio relative to NECA = 1).

30

Results

Table 1

Biological Data. A1, A3 R ceptor Gene Assay ECR


30

Example	A1	A3
1	2.70	>129
2	3.30	180
3	1.01	204
4	0.90	338
5	6.21	>116
6	1.27	5.00
17	3.90	57.3
19	1.62	>243
20	1.38	54.8
21	1.77	135
22	0.39	112
23	2.20	162
25	1.67	>288
27	3.02	>263
28	8.07	>99

CLAIMS

1. A compound of formula (I)

5



wherein R^2 represents C_{1-3} alkyl, halogen or hydrogen;

10

R^3 represents straight or branched alkyl group of 1-6 carbon atoms;

R^1 represents a group selected from

15


- (1) $-(alk)_n-$ (C_{3-7}) cycloalkyl, including bridged cycloalkyl, said cycloalkyl group optionally substituted by one or more substituents selected from OH, halogen, $-(C_{1-3})$ alkoxy, wherein (alk) represents C_{1-3} alkylene and n represents 0 or 1.

20

- (2) an aliphatic heterocyclic group of 4 to 6 membered rings containing at least one heteroatom selected from O, N or S optionally substituted by one or more substituents selected from the group consisting of $-(C_{1-3})$ alkyl, $-CO_2-(C_{1-4})$ alkyl, $-CO(C_{1-3})$ alkyl, $-S(=O)_n-(C_{1-3})$ alkyl, $CONR^aR^b$ (wherein R^a and R^b independently represent H or C_{1-3} alkyl) or $=O$, and where there is a sulfur atom in the heterocyclic ring, said sulfur is optionally substituted by $(=O)_n$ where n is 1 or 2.

25

- (3) Straight or branched C_{1-12} alkyl, optionally including one or more O, $S(=O)_n$, (where n is 0, 1 or 2) or N groups substituted within the alkyl chain, said alkyl optionally substituted by one or more of the following groups, phenyl, halogen, hydroxy or NR^aR^b wherein R^a and R^b both represent C_{1-3} alkyl or hydrogen.
- (4) a fused bicyclic aromatic ring



wherein B represents a 5 or 6 membered heterocyclic aromatic group containing 1 or more O, N or S atoms, wherein the bicyclic ring is attached to the nitrogen atom of formula (I) via a ring atom of ring A and ring B is optionally substituted by $-CO_2$ (C_{1-3} alkyl).

- (5) a phenyl group optionally substituted by one or more substituents selected from:
- halogen, $-SO_3H$, $-(alk)_nOH$, $-(alk)_n$ -cyano, $-(O)_n$ - C_{1-6} -alkyl (optionally substituted by one or more halogens), $-(alk)_n$ -nitro, $-(O)_m$ - $-(alk)_n$ - CO_2R^c , $-(alk)_n$ - $CONR^cR^d$, $-(alk)_n$ - COR^c , $-(alk)_n$ - SOR^e , $-(alk)_n$ - SO_2R^e , $-(alk)_n$ - $SO_2NR^cR^d$, $-(alk)_n$ - OR^c , $-(alk)_n$ - $(CO)_m$ - $NHSO_2R^e$, $-(alk)_n$ - $NHCOR^c$, $-(alk)_n$ - NR^cR^d wherein m and n are 0 or 1 and alk represents a C_{1-6} alkylene group or C_{2-6} alkenyl group.
- (6) A phenyl group substituted by a 5 or 6 membered heterocyclic aromatic group, said heterocyclic aromatic group optionally being substituted by C_{1-3} alkyl or NR^cR^d .

R^c and R^d may each independently represent hydrogen, or C_{1-3} alkyl or when part of a group NR^cR^d , R^c and R^d together with the nitrogen atom may form a 5 or 6 membered heterocyclic ring optionally containing other heteroatoms which heterocyclic ring may optionally be substituted further by one or more C_{1-3} alkyl groups

R^e represents C₁₋₃alkyl;

With the proviso that, when R³ represents C₁₋₆ alkyl, R² represents C₁₋₃ alkyl, R¹ cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C₁₋₃alkyl, trifluoromethyl, nitro, cyano,
 5 -CO₂R^c, -CONR^cR^d, -COR^c, -SOR^e, -SO₂R^e, -SO₃H, -SO₂NR^cR^d, -OR^c,
 -NHSO₂R^e, -NHCOR^c and -NR^cR^d;

and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof.

2. A compound according to claim 1 wherein R³ represents C₁₋₃ alkyl.
- 10 3. A compound according to claim 2 wherein R³ represents methyl or ethyl.
4. A compound according to claim 3 wherein R³ represents methyl.
5. A compound according to any preceding claim wherein R² represents hydrogen, methyl or halogen.
- 15 6. A compound according to claim 5 wherein R² represents hydrogen or methyl.
7. A compound according to any of claims 1-6 wherein R¹ represents (alk)_n-C₅₋₇- cycloalkyl wherein n is 0 or 1, optionally substituted by at least one substituent selected from halogen, C₁₋₃ alkoxy, and OH or is unsubstituted.
- 20 8. A compound according to claim 7 wherein the cycloalkyl group is unsubstituted or monosubstituted with fluorine.
9. A compound according to claim 7 or 8 wherein n is zero.
- 25 10. A compound according to any of claims 1-6 wherein R¹ represents a substituted or unsubstituted aliphatic heterocyclic group, which when substituted, the substituent being selected from the group consisting of C₁₋₃alkyl, CO₂-C₍₁₋₄₎ alkyl, =O, -CO- (C₁₋₃) alkyl, -S(=O)_n-C₍₁₋₃₎ alkyl (where n is 1 or 2), CONR^aR^b wherein R^a and R^b are defined in claim 1 and when

there is a heteroatom S in the ring this S is optionally substituted by $(=O)_n$ where n is 1 or 2.

11. A compound according to claim 10 wherein the substituent is CO_2-C_{1-4} alkyl or methyl.
- 5 12. A compound according to claim 11 wherein the aliphatic heterocyclic group is unsubstituted or the substituent is $CO_2-(C_{1-4})$ is alkyl and when the heteroatom is N, the substituent is directly attached to the ring N atom.
13. A compound according to any of claims 10-12 wherein the heterocyclic ring is 6 membered.
- 10 14. A compound according to claim 13 wherein the ring contains only one N, O or S heteroatom.
- 15 15. A compound according to any of claims 1-6 wherein R^1 represents a straight or branched alkyl of 1-6 carbon atoms optionally including at least one $S(=O)_2$, O or N substituted in the chain, the alkyl optionally further substituted by at least one group selected from OH, phenyl and fluorine.
16. A compound according to any of claims 1-6 wherein R^1 represents a phenyl group substituted by one or more substituents selected from OH, halogen $O_m(-alk)_nCO_2R^c$ and $(alk)_nOH$.
- 20 17. A compound according to claim 16 wherein the phenyl group is disubstituted in the 2, 4 positions.
18. A compound according to claim 17 wherein both substituents are halogen.
19. A compound according to claim 18 wherein the 2 substituent is fluoro and the 4 substituent is fluoro.
- 25 20. A compound according to claim 1-6 wherein R^1 represents a phenyl group substituted by a 5-tetrazolyl group this group itself optionally substituted by C_{1-3} alkyl.

21. A compound according to any of claims 1-6 wherein R¹ represents a fused group.




wherein B represents a furan ring optionally substituted by CO₂(C₁₋₃) alkyl.

22. A compound according to claim 21 wherein the furan ring is substituted in the 2 position.
23. A compound according to claim 1 selected from:
- 5'-O-Methyl-N-(tetrahydro-furan-3R-yl)-adenosine
 - N-(2R-Hydroxy-(R)-cyclopentyl)-5'-O-methyl-adenosine
 - 5'-O-Methyl-N-(tetrahydro-pyran-4-yl)-adenosine
 - N-(2S-Methoxy-(S)-cyclopentyl)-5'-O-methyl-adenosine
 - 5'-O-Methyl-N-(2S-methyl-tetrahydro-furan-3R-yl)-adenosine
 - N-(3-Chloro-4-hydroxy-phenyl)-5'-O-methyl-adenosine
 - 5'-O-Methyl-N-(1R-methyl-2-phenyl-ethyl)-adenosine
 - N-tert-Butyl-5'-O-methyl-adenosine
 - N-(2S-Fluoro-(S)-cyclopentyl)-5'-O-methyl-adenosine
 - N-(2,3-Dihydroxy-propylamino)-5'-O-methyl-adenosine
 - N-rel-[(1S,4R)-Bicyclo[2.2.1]hept-2R-yl]-5'-O-methyl-adenosine
 - 4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-piperidine-1-carboxylic acid ethyl ester
 - 5'-O-Methyl-N-[4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-adenosine
 - 3-[4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-phenyl]-(E)-acrylic acid
 - N-(4-Hydroxymethyl-phenyl)-5'-O-methyl-adenosine
 - {4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-phenoxy}-acetic acid
 - 5-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-9H-purin-6-ylamino]-benzofuran-2-carboxylic acid methyl ester
 - 5'-O-Methyl-N-(tetrahydro-thiopyran-4-yl)-adenosine
 - N-rel-[(1R,5R)-Bicyclo[3.2.0]hept-6S-yl]-5'-O-methyl-adenosine

- 4-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-2-methyl-9H-purin-6-ylamino]-piperidin-2-one
 5'-O-Methyl-N-(1S-methoxymethyl-2-methyl-propyl)-adenosine
 N-(2-Hydroxy-1R-methyl-ethyl)-5'-O-methyl-adenosine
 5 N-(2-Fluoro-1R-methyl-ethyl)-5'-O-methyl-adenosine
 N-(1S-Fluoromethyl-2-methoxy-ethyl)-5'-O-methyl-adenosine
 N-(3-Amino-propyl)-5'-O-methyl-adenosine
 2-[9-(3R,4S-Dihydroxy-5R-methoxymethyl-tetrahydro-furan-2R-yl)-2-methyl-9H-purin-6-ylamino]-ethanesulfonic acid methylamide
 10 N-Cyclopentyl-2-methyl-5'-O-methyl-adenosine
 N-Cyclopropylmethyl-2-methyl-5'-O-methyl-adenosine
24. A compound according to any preceding claim with little or no activity at the A3 receptor.
25. A compound according to any of claims 1-24 for use in therapy.
- 15 26. A pharmaceutical composition comprising a compound according to claims 1-24 together with a pharmaceutical carrier and/or excipient.
27. Use of a compound according to any of claim 1-24 for the manufacture of a medicament for the treatment of a patient suffering from a condition where there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnoea.
 20
28. A method of treating a patient suffering from a condition where there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnoea comprising administering a therapeutically effective amount of a compound according to any of claims 1-24.
 25
29. A method of preparing a compound according to any of claims 1-24 which comprises reacting a compound of formula (II).
 30


37



wherein L represents a leaving group and P¹ and P² represent protecting groups or H with a compound R¹NH₂ or a salt thereof under basic conditions. R¹, R² and R³ being defined in claim 1.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 19/167, A61K 31/70	A3	(11) International Publication Number: WO 99/24451 (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: PCT/EP98/07023 (22) International Filing Date: 6 November 1998 (06.11.98) (30) Priority Data: 9723590.7 8 November 1997 (08.11.97) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ELDRED, Colin, David [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). PENNELL, Andrew, Michael, Kenneth [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). (74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 19 August 1999 (19.08.99)
(54) Title: ADENOSINE A ₁ RECEPTOR AGONISTS <div style="text-align: center;">  <p>(I)</p> </div> (57) Abstract <p>A compound of formula (I), wherein R² represents C₁₋₃alkyl, halogen or hydrogen; R³ represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R³ represents C₁₋₆alkyl, R² represents C₁₋₃alkyl, R¹ cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C₁₋₃alkyl, trifluoromethyl, nitro, cyano, -CO₂R^c, -CONR^cR^d, -COR^c, -SOR^a, -SO₂R^a, -SO₃H, -SO₂NR^cR^d, -OR^c, -NHSO₂R^c, -NHCOR^c and -NR^cR^d; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A₁ receptor.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/07023

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07H19/167 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 33591 A (NOVONORDISK AS) 18 September 1997 see page 9, line 20 - page 17, line 5 ---	1, 24-29
A	WO 95 07921 A (NOVONORDISK AS ; LAU JESPER (DK); KNUTSEN LARS JACOB STRAY (DK)) 23 March 1995 see the whole document ---	1, 24-29
A	LUBITZ VON D K J E ET AL: "REDUCTION OF POSTICHEMIC BRAIN DAMAGE AND MEMORY DEFICITS FOLLOWING TREATMENT WITH THE SELECTIVE ADENOSINE A1 RECEPTOR AGONIST" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 302, no. 1/03, 1 January 1996, pages 43-48, XP002035719 see abstract --- -/--	1, 24-29



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

4 June 1999

Date of mailing of the international search report

18/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/07023

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 97 43300 A (GLAXO GROUP LTD ;ELLIS FRANK (GB); SWANSON STEPHEN (GB); COUSINS R) 20 November 1997 see the whole document ---	1,24-29
P,A	WO 98 01426 A (CHOI SLEDESKI YONG MI ;PAULS HENRY W (US); EWING WILLIAM R (US); M) 15 January 1998 see page 49, line 14 - line 15 see page 54, line 5 - line 9 see claim 1 -----	1,24-29

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/07023

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 28
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/EP 98/07023

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9733591 A	18-09-1997	AU 2022497 A AU 2022597 A WO 9733590 A	01-10-1997 01-10-1997 18-09-1997
WO 9507921 A	23-03-1995	AU 678053 B AU 7651994 A CA 2171940 A EP 0719275 A FI 961219 A NO 961071 A NZ 273284 A US 5589467 A ZA 9407201 A	15-05-1997 03-04-1995 23-03-1995 03-07-1996 15-05-1996 15-05-1996 24-03-1997 31-12-1996 18-03-1996
WO 9743300 A	20-11-1997	AU 2896197 A EP 0901499 A	05-12-1997 17-03-1999
WO 9801426 A	15-01-1998	AU 3645497 A EP 0912520 A NO 990063 A	02-02-1998 06-05-1999 08-03-1999